Table 2–

Treatment-emergent adverse events with ≥10% incidence during first-line therapy

Adverse event	Event rate by treatment arm and grade (%)
	Pazopanib (n = 34)			Temsirolimus (n = 35)
	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4
Diarrhea	71	3	0	17	0	0
Fatigue	65	21	0	46	17	0
Nausea	62	9	0	20	0	0
Hypertension	53	29	0	11	6	0
Rash maculopapular	53	3	0	29	3	0
Hypothyroidism	50	0	0	0	0	0
Skin hypopigmentation	47	0	0	0	0	0
Dysgeusia	44	0	0	20	0	0
Vomiting	44	6	0	6	0	0
Anorexia	38	0	0	14	3	0
Aspartate aminotransferase increased	35	9	0	6	0	0
Proteinuria	35	3	0	26	6	0
Alanine aminotransferase increased	32	12	0	0	0	0
Hyperglycemia	32	0	0	63	6	3
Mucositis oral	32	0	0	43	6	0
Alkaline phosphatase increased	29	6	0	26	0	0
Constipation	26	3	0	17	0	0
Pain	26	3	0	9	3	0
Weight loss	26	0	0	9	0	0
Anemia	24	0	0	60	17	0
Hyponatremia	24	6	0	6	0	0
Platelet count decreased	24	3	0	9	0	0
Creatinine increased	21	0	3	31	0	0
Hyperkalemia	21	0	0	6	0	0
Hypoalbuminemia	21	0	0	9	0	0
White blood cell decreased	21	0	0	11	0	0
Abdominal pain	18	0	0	11	0	0
Bilirubin increased	18	3	0	0	0	0
Lymphocyte count decreased	18	3	0	9	0	0
Alopecia	15	0	0	6	0	0
Dyspnea	15	0	0	17	0	0
Hoarseness	15	0	0	0	0	0
Hypomagnesemia	15	0	0	0	0	0
Palmar-plantar
erythrodysesthesia	15	0	0	0	0	0
syndrome
Paresthesia	15	0	0	9	0	0
Chest wall pain	12	0	0	3	0	0
Edema limbs	12	0	0	26	3	0
Hypertriglyceridemia	9	0	0	57	3	0
Hypokalemia	3	0	0	14	0	0
Cholesterol high	0	0	0	31	0	0
Dry skin	0	0	0	14	0	0

Note: Incidence was ≥10% for at least one of the first-line agents.